Pentamidine Movement across the Murine Blood-Brain and Blood-Cerebrospinal Fluid Barriers: Effect of Trypanosome Infection, Combination Therapy, P-Glycoprotein, and Multidrug Resistance-Associated Protein
Authors:
- Murat DogruelMDMurat Dogruel
- Jean RodgersJRJean Rodgers
- Harry Pieter De KoningHKHarry Pieter De Koning
- Sarah Ann ThomasSTSarah Ann Thomas
- 1 June 2009
- journal article
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 329 (3) , 967-977
Abstract
During the first stage of human African trypanosomiasis (HAT), Trypanosoma brucei gambiense is found mainly in the blood, and pentamidine treatment is used. Pentamidine is predominantly ineffective once the parasites have invaded the central nervous system (CNS). This lack of efficacy is thought to be due to the inability of pentamidine to cross the blood-brain barrier, although this has never been explored directly. This study addresses this using brain perfusion in healthy mice, P-glycoprotein-deficient mice, and in a murine model of HAT (T. brucei brucei). The influence of additional antitrypanosomal drugs on pentamidine delivery to the CNS also was investigated. Results revealed that [3H]pentamidine can cross the blood-brain barrier, although a proportion was retained by the capillary endothelium and failed to reach the healthy or trypanosome-infected brain (up to day 21 p.i.). The CNS distribution of pentamidine was increased in the final (possibly terminal) stage of trypanosome infection, partly because of loss of barrier integrity (days 28–35 p.i.) as measured by [14C]sucrose and [3H]suramin. Furthermore, pentamidine distribution to the CNS involved influx and efflux [via P-glycoprotein and multidrug resistance-associated protein (MRP)] transporters and was affected by the other antitrypanosomal agents, suramin, melarsoprol, and nifurtimox, but not eflornithine. These interactions could contribute to side effects or lead to the development of parasite resistance to the drugs. Thus, great care must be taken when designing drug combinations containing pentamidine or other diamidine analogs. However, coadministration of P-glycoprotein and/or MRP inhibitors with pentamidine or other diamidines might provide a means of improving efficacy against CNS stage HAT.Keywords
This publication has 40 references indexed in Scilit:
- The transport of anti-HIV drugs across blood–CNS interfaces: Summary of current knowledge and recommendations for further researchAntiviral Research, 2009
- The blood–brain barrier significantly limits eflornithine entry into Trypanosoma brucei brucei infected mouse brain1Journal of Neurochemistry, 2008
- Differential expression of the multidrug resistance‐related proteins ABCb1 and ABCc1 between blood‐brain interfacesJournal of Comparative Neurology, 2008
- Nifurtimox-Eflornithine Combination Therapy for Second-Stage Trypanosoma brucei gambiense Sleeping Sickness: A Randomized Clinical Trial in CongoClinical Infectious Diseases, 2007
- Distribution of Suramin, an Antitrypanosomal Drug, across the Blood-Brain and Blood-Cerebrospinal Fluid Interfaces in Wild-Type and P-Glycoprotein Transporter-Deficient MiceAntimicrobial Agents and Chemotherapy, 2007
- Modulation of Leishmania ABC Protein Gene Expression through Life Stages and among Drug-Resistant ParasitesEukaryotic Cell, 2006
- Genetic dissection of the function of mammalian P-glycoproteinsTrends in Genetics, 1997
- Passage of a δ‐Opioid Receptor Selective Enkephalin, [d‐Penicillamine2,5]Enkephalin, Across the Blood‐Brain and the Blood‐Cerebrospinal Fluid BarriersJournal of Neurochemistry, 1996
- Pentamidine concentrations in plasma, whole blood and cerebrospinal fluid during treatment of Trypanosoma gambiense infection in Côte d'IvoireTransactions of the Royal Society of Tropical Medicine and Hygiene, 1991
- Distribution of Pentamidine in Patients with AIDSThe Journal of Infectious Diseases, 1988